Paul Smith currently works as the Senior Director of Preclinical Pharmacology within the Incyte Research Institute (Incyte Corporation) with a focus on autoimmune and inflammatory diseases.  Dr. Smith received his PhD in Immunology from Imperial College London (University of London) and subsequently completed post-doctoral training at the Biomedical Primate Research Center (the Netherlands). Since 2005 Dr Smith has held…Read more

After completing her chemistry studies at the Swiss Federal Institute of Technology (ETH Zurich) Daniela Angst pursued a PhD at the Paul Scherrer Institute and the University of Basel in radiopharmaceutical chemistry. Following a postdoc at the University of California (UCLA) in total synthesis she joined Novartis as a medicinal chemist. She has worked on several…Read more

Michael Mingueneau is an immunologist/neuroimmunologist experienced with target identification, validation and advancing drug discovery programs in the fields of Immunology, Neuroimmunology and Autoimmunity. As R&D project and group lead at Biogen, he directs a group of scientists on cross-functional project teams to develop therapeutics for the treatment for both relapsing and progressive forms of Multiple Sclerosis. Before joining the…Read more

Mike joined Biogen in 2018 as a Principal Scientist, supporting research activities for several multiple sclerosis (MS) programs. In 2020, he became an Associate Medical Director for the MS development unit, running phase I and phase II clinical trials. Mike received his MD/PhD (Pharmacology) from the University of Wisconsin – Madison. He did his graduate…Read more